Aegis Capital Corp. acted as Exclusive Placement Agent on a $19.5 Million Private Placement Priced At-the-Market for Sunshine Biopharma Inc. (NASDAQ: SBFM)
Sunshine Biopharma Inc. (NASDAQ:SBFM) has successfully completed a $19.5 million private placement, with Aegis Capital Corp. serving as the exclusive placement agent. This financing will support the advancement of its lead compound, SBFM-PL4, targeting COVID-19, and Adva-27a, an anticancer drug effective against multidrug-resistant cancer cells. Clinical trials for pancreatic cancer are planned in collaboration with McGill University. The company holds all patents related to Adva-27a, highlighting its strong position in developing innovative therapeutics.
- Successful completion of $19.5 million private placement enhances liquidity.
- Advancement of SBFM-PL4 targeting COVID-19 indicates progress in treatment development.
- Adva-27a shows effectiveness against multidrug-resistant cancer cells.
- Clinical trials for pancreatic cancer planned at reputable McGill University.
- None.
NEW YORK, NY / ACCESSWIRE / April 28, 2022 / Aegis Capital Corp. acted as Exclusive Placement Agent on a
About Sunshine Biopharma, Inc.
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 5.3 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. The Company is currently advancing the development of SBFM-PL4 in collaboration with the University of Georgia, College of Pharmacy. In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.
For more information, visit www.sunshinebiopharma.com
About Aegis Capital Corporation
Aegis Capital Corporation ("Aegis") has been in the wealth management and investment banking business since 1984. Aegis is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis also provides research and sales and trading services to institutional investors. Aegis offers its investment representatives a conflict free service platform and is able to provide a full-range of products and services including investment banking, wealth management, insurance, retirement planning, structured products, private equity, alternatives, equity research, fixed income and special purpose vehicles.
For more information about this offering or Investment Banking Services please email Banking@aegiscap.com or call (212) 813-1010.
Brokerage and investment advisory services are offered through Aegis Capital Corporation, a member of FINRA and SIPC. Investment and insurance products offered are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.
SOURCE: Aegis Capital Corp.
View source version on accesswire.com:
https://www.accesswire.com/699266/Aegis-Capital-Corp-acted-as-Exclusive-Placement-Agent-on-a-195-Million-Private-Placement-Priced-At-the-Market-for-Sunshine-Biopharma-Inc-NASDAQ-SBFM
FAQ
What was the amount of the private placement for Sunshine Biopharma (SBFM)?
What are the main projects Sunshine Biopharma is working on?
Where will the clinical trials for pancreatic cancer be conducted?
Who acted as the placement agent for Sunshine Biopharma's private placement?